Allocation and validation of the second revision of the International Staging System in the ICARIA-MM and IKEMA studies
Abstract The International Staging System for multiple myeloma recently underwent a second revision (R2-ISS) to include gain/amplification of 1q21 and account for the additive prognostic significance of multiple high-risk features. The phase 3 ICARIA-MM (isatuximab–pomalidomide–dexamethasone vs. pom...
Wedi'i Gadw mewn:
| Prif Awduron: | , , , , , , , , , , , , , , , , , |
|---|---|
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
Nature Publishing Group
2024-11-01
|
| Cyfres: | Blood Cancer Journal |
| Mynediad Ar-lein: | https://doi.org/10.1038/s41408-024-01149-w |
| Tagiau: |
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|
